Last reviewed · How we verify

Myramistin

Megainpharm GmbH · discontinued Small molecule

Myramistin is a Small molecule drug developed by Megainpharm GmbH. It is currently in discontinued development.

At a glance

Generic nameMyramistin
SponsorMegainpharm GmbH
ModalitySmall molecule
Therapeutic areaOther
Phasediscontinued

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Myramistin

What is Myramistin?

Myramistin is a Small molecule drug developed by Megainpharm GmbH.

Who makes Myramistin?

Myramistin is developed by Megainpharm GmbH (see full Megainpharm GmbH pipeline at /company/megainpharm-gmbh).

What development phase is Myramistin in?

Myramistin is in discontinued.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing